Genflow meets primary endpoint in SLAB dog trial
Genflow announced that its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial met its primary endpoint. The randomized, blinded study enrolled 24 beagle dogs aged over 10 years, allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 group,
<p>Genflow announced that its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial met its primary endpoint. The randomized, blinded study enrolled 24 beagle dogs aged over 10 years, allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 group, </p>